Preclinical development of FL-091, a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers

被引：0
|
作者：
Zhang, J. [1 ]
Yang, J. [1 ]
Liu, F. [1 ]
Wong, N. C. L. [1 ]
Thrane, K. T. [2 ]
Hallund, M. W. [2 ]
Gronlund, R. V. [2 ]
机构：
[1] Full Life Technol, Shanghai, Peoples R China
[2] Minerva Imaging ApS, Olstykke, Denmark
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-676
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 46 条
  • [31] A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
    Andrew L. Coveler
    Andrew H. Ko
    Daniel V. T. Catenacci
    Daniel Von Hoff
    Carlos Becerra
    Nancy C. Whiting
    Jing Yang
    Brian Wolpin
    Investigational New Drugs, 2016, 34 : 319 - 328
  • [32] Preclinical development of YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) with novel topoisomerase I inhibitor-based linker- payload for treatment of solid tumors
    Xiao, Liang
    Lian, Wei
    Liu, Qigang
    Zong, Qing
    Song, Shuai
    Stann, Sasha
    Cai, Jiaqiang
    Xue, Tongtong
    CANCER RESEARCH, 2024, 84 (06)
  • [33] DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models
    Yukiura, Mayuko
    Takano, Kohei
    Takahashi, Kazuki
    Zembutsu, Akiko
    Kitamura, Michiko
    Shiose, Yoshinobu
    Honda, Kokichi
    Oyama, Kazunori
    Obuchi, Wataru
    Yamada, Makiko
    Goto, Riki
    Sakurai, Ken
    Kumagai, Kazuyoshi
    Kagari, Takashi
    Abe, Yuki
    Agatsuma, Toshinori
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
    Baron, Jessica M.
    Boster, Bonnie L.
    Barnett, Chad M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (02) : 132 - 142
  • [35] Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer
    Jarvelainen, Harri
    Lin, Wei-Hsiang
    Kang, Moorim
    Zhou, Xiaojie
    Place, Robert F.
    Li, Long-Cheng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Antibody-drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase
    Hudson, Rachel
    Yao, Hang-Ping
    Suthe, Sreedhar Reddy
    Patel, Dhavalkumar
    Wang, Ming-Hai
    CURRENT CANCER DRUG TARGETS, 2022, 22 (04) : 312 - 327
  • [37] A novel pegylated bispecific antibody-drug conjugate (P-BsADC) JY207b targeting cancers co-expressing PD-L1 and CD47
    Wen, Yu
    Liu, Shumin
    Lyu, Weidong
    Lei, Yang
    Tan, Shuangyu
    Wu, Zibin
    Yin, Shuqiang
    Zhuo, Qiudong
    Wu, Dechun
    CANCER RESEARCH, 2024, 84 (06)
  • [38] NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors-A phase 1/2 clinical trial.
    Tolcher, Anthony W.
    Meric-Bernstam, Funda
    McKean, Meredith
    Beerli, Roger R.
    Waldmeier, Lorenz
    Gebleux, Remy
    Hellmann, Ina
    Chrom, Pawel
    Grawunder, Ulf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] Targeting TIP1 with a novel radiosensitizing antibody-drug conjugate (ADC) enhances the therapeutic efficacy of radiation for non-small cell lung carcinoma treatment.
    Lewis, Calvin
    Singh, Abhay K.
    Thotala, Dinesh
    Hallahan, Dennis E.
    Kapoor, Vaishali
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Development and Characterization of SPY002, a Novel Extended Half-life Monoclonal Antibody Drug Candidate Targeting TL1A for the Treatment of IBD
    Zhu, E.
    Rios, D.
    Milligan, J.
    Ministro, J.
    Friedman, J.
    Nguyen, D.
    Spencer, A.
    Oh, J.
    Shaheen, H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1656 - I1656
12345